Interplay of drug metabolism and transport: A real phenomenon or an artifact of the site of measurement?

Molecular Pharmaceutics

Volumn 6, Issue 6, 2009, Pages 1756-1765

  Endres, Christopher J ^a,b   Endres, Michael G ^c   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b AMGEN INC   (United States)

^c Columbia University ^*  (United States)

Author keywords

Drug interactions; Drug metabolism; Drug transport; Hepatic clearance models; Interplay; PBPK

Indexed keywords

DRUG METABOLIZING ENZYME;

ARTICLE; ARTIFACT; BILIARY EXCRETION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG TRANSPORT; EFFUSION; KINETICS; LIVER CELL; LIVER CLEARANCE; METABOLIC CLEARANCE RATE; PRIORITY JOURNAL; SIMULATION;

ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; LIVER; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS;

EID: 71949102481     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp9002392     Document Type: Article

References (24)

1. Rowland, M.; Benet, L. Z.; Graham, G. G. Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1973, 1 (2), 123-136
2. Wilkinson, G. R.; Shand, D. G. Commentary: a physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 1975, 18 (4), 377-390
3. McGinnity, D. F.; Soars, M. G.; Urbanowicz, R. A.; Riley, R. J. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos. 2004, 32 (11), 1247-1253
4. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 1999, 27 (11), 1350-1359
5. Ito, K.; Iwatsubo, T.; Kanamitsu, S.; Ueda, K.; Suzuki, H.; Sugiyama, Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev. 1998, 50 (3), 387-412.
6. de Lannoy, I. A.; Pang, K. S. Effect of diffusional barriers on drug and metabolite kinetics. Drug Metab. Dispos. 1987, 15 (1), 51-58 (Pubitemid 17014506)
7. Kwon, Y.; Morris, M. E. Membrane transport in hepatic clearance of drugs. I: Extended hepatic clearance models incorporating concentration-dependent transport and elimination processes. Pharm. Res. 1997, 14 (6), 774-779 (Pubitemid 27281673)
8. Sirianni, G. L.; Pang, K. S. Organ clearance concepts: new perspectives on old principles. J. Pharmacokinet. Biopharm. 1997, 25 (4), 449-470 (Pubitemid 28186446)
9. Liu, L.; Pang, K. S. The roles of transporters and enzymes in hepatic drug processing. Drug Metab. Dispos. 2005, 33 (1), 1-9.
10. Shitara, Y.; Sugiyama, Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 2006, 112 (1), 71-105.
11. Adachi, T.; Nakagawa, H.; Hagiya, Y.; Yasuoka, T.; Ishikawa, T. Transport-metabolism interplay: LXRR-mediated induction of human ABC transporter ABCC2 (cMOAT/MRP2) in HepG2 cells. Mol. Pharmaceutics 2009. DOI: 10.1021/mp9001156.
12. Meyer Zu Schwabedissen, H. E.; Kim, R. B. Hepatic OATP1B Transporters and Nuclear Receptors PXR and CAR: Interplay, Regulation of Drug Disposition Genes, and Single Nucleotide Polymorphisms. Mol. Pharmaceutics 2009. DOI: 10.1021/mp9000298.
13. Nies, A. T.; Schwab, M.; Keppler, D. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin. Drug Metab. Toxicol. 2008, 4 (5), 545-568 (Pubitemid 351890738)
14. Custodio, J. M.; Wu, C. Y.; Benet, L. Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Delivery Rev. 2008, 60 (6), 717-733
15. Yang, J.; Jamei, M.; Yeo, K. R.; Tucker, G. T.; Rostami-Hodjegan, A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab. 2007, 8 (7), 676-684 (Pubitemid 47578116)
16. Baker, M.; Parton, T. Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake. Xenobiotica 2007, 37 (10-11), 1110-1134 (Pubitemid 350035537)
17. Kusuhara, H.; Sugiyama, Y. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab. Pharmacokinet. 2009, 24 (1), 37-52.
18. Kitamura, S.; Maeda, K.; Sugiyama, Y. Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans. Naunyn-Schmiedeberg's Arch. Pharmacol. 2008, 377 (4-6), 617-628
19. Lam, J. L.; Okochi, H.; Huang, Y.; Benet, L. Z. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab. Dispos. 2006, 34 (8), 1336-1344
20. Kageyama, M.; Namiki, H.; Fukushima, H.; Ito, Y.; Shibata, N.; Takada, K. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol. Pharm. Bull. 2005, 28 (2), 316-322 (Pubitemid 40880016)
21. Frassetto, L. A.; Poon, S.; Tsourounis, C.; Valera, C.; Benet, L. Z. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin. Pharmacol. Ther. 2007, 81 (6), 828-832
22. Olinga, P.; Elferink, M. G.; Draaisma, A. L.; Merema, M. T.; Castell, J. V.; Perez, G.; Groothuis, G. M. Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur. J. Pharm. Sci. 2008, 33 (4-5), 380-389
23. Lamba, J.; Strom, S.; Venkataramanan, R.; Thummel, K. E.; Lin, Y. S.; Liu, W.; Cheng, C.; Lamba, V.; Watkins, P. B.; Schuetz, E. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin. Pharmacol. Ther. 2006, 79 (4), 325-338
24. Cerveny, L.; Svecova, L.; Anzenbacherova, E.; Vrzal, R.; Staud, F.; Dvorak, Z.; Ulrichova, J.; Anzenbacher, P.; Pavek, P. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab. Dispos. 2007, 35 (7), 1032-1041 (Pubitemid 46956421)